许元基, 邱素芳, 林少俊, 宗井凤, 郑崴, 黄朝斌, 潘建基. 104例Ⅱ期鼻咽癌诱导化疗的回顾性同期对照研究[J]. 中国肿瘤临床, 2012, 39(24): 2018-2021. DOI: 10.3969/j.issn.1000-8179.2012.24.008
引用本文: 许元基, 邱素芳, 林少俊, 宗井凤, 郑崴, 黄朝斌, 潘建基. 104例Ⅱ期鼻咽癌诱导化疗的回顾性同期对照研究[J]. 中国肿瘤临床, 2012, 39(24): 2018-2021. DOI: 10.3969/j.issn.1000-8179.2012.24.008
shu
Yuanji XU, Sufang QIU, Shaojun LIN, Jingfeng ZONG, Wei ZHENG, Chaobin HUANG, Jianji PAN. A Retrospective Concurrent Control Study of Induction Chemotherapy in 104 Patients with Stage Ⅱ Nasopharyngeal Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(24): 2018-2021. DOI: 10.3969/j.issn.1000-8179.2012.24.008
Citation: Yuanji XU, Sufang QIU, Shaojun LIN, Jingfeng ZONG, Wei ZHENG, Chaobin HUANG, Jianji PAN. A Retrospective Concurrent Control Study of Induction Chemotherapy in 104 Patients with Stage Ⅱ Nasopharyngeal Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(24): 2018-2021. DOI: 10.3969/j.issn.1000-8179.2012.24.008
shu

104例Ⅱ期鼻咽癌诱导化疗的回顾性同期对照研究

A Retrospective Concurrent Control Study of Induction Chemotherapy in 104 Patients with Stage Ⅱ Nasopharyngeal Carcinoma

    摘要
  • 摘要:
      目的  探讨诱导化疗对Ⅱ期鼻咽癌远期疗效的影响。
      方法  收集福建省肿瘤医院放疗科收治经病理组织学证实的初诊Ⅱ期鼻咽癌患者104例，按治疗方式分为诱导化疗联合放疗组（放化组）和单纯放疗组（单放组）。比较两组患者的5年生存率。
      结果  全组中位随访时间为61（14~74）个月。放化组62例，单放组42例。放化组和单放组的5年无局部区域复发生存率（LRRFS）、无远处转移生存率（DMFS）、总生存率（OS）分别为92.9%和86.9%（P=0.859）、91.9%和97.6%（P=0.253）、94.3%和82.9%（P=0.164）。进一步分析结果显示，放化组中的T2N0、T1N1、T2N1期的DMFS分别为100.0%、100.0%、78.3%（P=0.010）；OS分别为100.0%、100.0%、85.2%（P=0.079）；LRRFS分别为83.3%、96.9%、89.9%（P=0.393）。
      结论  诱导化疗联合放疗未能提高Ⅱ期鼻咽癌患者的生存率。但T2N1期患者有较高的远处转移风险，可能需要行系统化疗。

     

    Abstract:
      Objective  This work aims to investigate the long-term effect of induction chemotherapy (ICT) in patients with stage Ⅱ nasopharyngeal carcinoma (NPC).
      Methods  A total of 104 patients with stage Ⅱ NPC were divided into two groups based on different methods of the therapy. One group was treated by ICT followed by radiotherapy (RT) (Group A), whereas the other group was treated by RT alone (Group B). The five-year survival rates in the two groups were compared.
      Results  The median follow-up time was 61 months(range, 14–74 months). A total of 62 and 42 patients were assigned in Groups A and B, respectively. The five-year loco-regional recurrence free survival (LRRFS), distant metastasis free survival (DMFS), and overall survival (OS) rates for Groups A and B were 92.9% vs. 86.9%(P=0.859), 91.9% vs. 97.6% (P=0.253), and 94.3% vs. 82.9% (P=0.164), respectively. Further analysis revealed that the five-year DMFS, OS, and LRRFS rates for stage T2N0, T1N1, and T2N1 cases were 100.0% vs. 100.0% vs. 78.3% (P=0.010), 100.0% vs. 100.0% vs. 85.2% (P=0.079), and 83.3% vs. 96.9% vs. 89.9% (P=0.393) in Group A.
      Conclusions  The survival rates of patients with stage Ⅱ NPC did not improve in Group A. However, a higher risk of distant failure was observed in stage T2N1 cases, which may need systemic chemotherapy.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回